Clinical Trials
Enrolling Trials
71-80 of 169
CIRB, Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Genitourinary
Adult
To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can improve PFS compared to abiraterone acetate alone.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzRice Clinic Medical Center
2501 Main
Stevens Point, WI 54481
CIRB, A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Leukemia
Adult
The purpose of this study is to perform further clinical, dental, biochemical, family, genetic and imaging evaluation of adults with persistent hypophosphatasemia who also harbor pathogenic, likely pathogenic or ALPL variants of uncertain significance and/or have elevated ALP substrates to more fully characterize this cohort and to determine what proportion may have previously unrecognized adult HPP.
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Hematology
Adult
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Leukemia
Adult
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
Cancer Symptom Management
Adult
Evaluate the change in level of self-reported financial burden from baseline (within 60 days of diagnosis) to 12 months after diagnosis of colon or rectal cancer treated with curative-intent.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
CIRB, Molecular Analysis for Therapy Choice (MATCH)
Miscellaneous Neoplasm
Adult
0401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 3
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
zzzLakeview Medical Center
1700 West Stout Street
Rice Lake, WI 54868
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
zzzSacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
zzzSt. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
CIRB, MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
Mutations
Adult
ct.govtest1
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol Z1H: Phase 2 STudy of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Mutations
Adult
The purpose of this study is to examine possible anatomic differences in brain receptive and expressive language centers in Bardet-Biedl syndrome (BBS) compared to normal age and gender matched monolingual controls using functional magnetic resonance imaging 9fMARI).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Mutations
Adult
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Mutations
Adult
We hypothesize that the property of ovarian tumors to raise serum calcium and lower serum albumin can be exploited to detect ovarian cancer earlier in their natural history. We will test that hypothesis in a case-control study in which changes in serum calcium and albumin levels in the medical records of women with ovarian cancer are compared to those of control women without ovarian cancer over several years. We hypothesize that relative to controls, women with ovarian cancer will show a significant increase (positive slope) in their albumin-adjusted calcium levels and a negative slope in their total albumin levels. In normal women, total calcium levels fluctuate only about 2% during their lifetime . Thus a pattern of rising calcium is abnormal (and is otherwise uncommon). Moreover, this pattern of rising calcium and declining albumin should be identified readily by a computer algorithm. A second objective of this study is to produce an algorithm that would ¿flag¿ women with this pattern. These women could be referred for increased ovarian cancer surveillance, leading to earlier detection of ovarian cancer. Thus, our Specific Aims are to:
1. Test the hypothesis that, compared to women who do not have a diagnosis of ovarian cancer, women with a diagnosis of ovarian cancer will show a significant increase in their serum albumin-adjusted calcium and serum albumin. If observed, we will develop a computer algorithm that describes this trend in calcium/albumin and enables the prediction of ovarian cancer.
2. Because ovarian cancer is associated with reduced hepatic synthesis of albumin, we will explore whether the addition of data regarding other liver enzymes, e.g., alkaline phosphatase and ALT (also available from the CMP), can aid in the discrimination of ovarian cancer. This exploratory aim is justifiable because multiple reports indicate that alkaline phosphatase levels are increased in sera and in ovarian tissue from women with ovarian cancer , .
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449